I
Ingo Hilgendorf
H指数:39
被引数:7,074
浏览量:0
个人简介
暂无内容
教育背景
暂无内容
工作经历
暂无内容
荣誉奖项
暂无内容
Inclisiran vs bempedoic acid for low-density lipoprotein cholesterol lowering in high-risk patients: the VICTORION-challenge trial
inclisiran与bempedoic酸在高风险患者中降低低密度脂蛋白胆固醇的疗效比较:VICTORION-challenge试验
European Heart Journal
IF35.6
Plasma infrared molecular fingerprinting stratifies residual risk in coronary artery disease and reflects clonal haematopoiesis-associated biology
血浆红外分子指纹分析可分层冠状动脉疾病中的残余风险并反映与克隆性造血相关的生物学
European Heart Journal
IF35.6
A quantitative method to estimate free interleukin-6 among patients treated with the interleukin-6 ligand inhibitor ziltivekimab: comparison to C-reactive protein with implications for the ZEUS, HERMES, and ARTEMIS cardiovascular outcomes trials
一种用于估算接受白细胞介素-6配体抑制剂ziltivekimab治疗的患者中游离白细胞介素-6的定量方法:与C反应蛋白的比较及其对ZEUS、HERMES和ARTEMIS心血管结局试验的启示
Atherosclerosis
IF5.7
Enhanced risk for recurrent adverse cardiovascular events in homozygous carriers of the T-allele of CD40 SNP rs1883832
纯合子携带者CD40 SNP rs1883832 T等位基因的复发性不良心血管事件风险增加
Atherosclerosis
IF5.7
Radial Versus Femoral Secondary Access in Patients Undergoing TAVI : Rationale and Design of the RADIAL-TAVI Trial
桡动脉与股动脉二次入路在经导管主动脉瓣置换术患者中的应用比较:RADIAL-TAVI试验的合理性与设计方案
Expanding the Role of Implantable Loop Recorders: Diagnostic and Therapeutic Yields Across Seven Clinical Indications in 388 Real-World Patients
扩展植入式环状记录仪的应用范围:388例真实世界患者中七种临床适应症的诊断与治疗效果
Low-density lipoprotein cholesterol drives multinucleated giant cell formation in response to mycobacterium bovis Bacille Calmette-Guérin
低密度脂蛋白胆固醇驱动巨噬分枝杆菌牛分枝杆菌卡介苗反应中的多核巨细胞形成
Scientific Reports
IF3.9
Endothelial CD40L serves as a pro-atherogenic adhesion receptor in the inflamed vasculature
内皮CD40L在炎症血管中充当促动脉粥样硬化的黏附受体。
Atherosclerosis
IF5.7
Fibrin clot strength is associated with increased risk of major adverse cardiac events after TAVR
纤维蛋白凝块强度与TAVR术后主要不良心血管事件风险增加相关
NLRP3 mediates lipid-driven macrophage proliferation in established atherosclerosis
NLRP3介导脂质驱动的巨噬细胞增殖,在已建立的动脉粥样硬化中发挥作用

